FOOD FOR THOUGHT: Watch the Christopher Moraes PhD VIDEO, then read these 5 high impact papers from 2025-2026 that pertain to his work and extend the conversation.
Here are 5 high-impact papers from 2025–2026 that are especially relevant to Christopher Moraes’ work on microenvironmental control in stem-cell derived pancreatic progenitor/islet production, and to the broader space of stem-cell islet differentiation, scale-up, and implantation in humans.
1) Reichman TW et al., 2025 — Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes (NEJM)
This landmark clinical paper reports interim results of the Phase 1–2 FORWARD trial (zimislecel/VX-880) showing that transplantation of fully differentiated, allogeneic stem-cell derived islets led to engraftment, restored C-peptide, improved glycemic control, elimination of severe hypoglycemia, and high rates of insulin independence at 12 months in people with T1D. (PubMed)
Why it’s high impact:
• First major clinical evidence that lab-produced islets can function in humans.
• Highlights the translational relevance of improving differentiation and scaling production — directly tied to microenvironment control platforms like the one Moraes develops.
2) Dadheech N et al., 2025 — Scale-Up Manufacturing of SC-Islets Using Vertical Wheel Bioreactors (npj Regenerative Medicine)
This paper demonstrates scalable differentiation of human iPSC-derived islets in Vertical Wheel® bioreactor suspension systems, achieving a ~12-fold increase in islet equivalents without compromising maturity or functional response in preclinical models. (Nature)
Why it’s high impact:
• Addresses practical scalability and batch consistency, complementing microenvironment strategies to control aggregate size and differentiation quality.
3) Filatov E et al., 2026 — CCL22-expressing SC-Islet Grafts Recruit Regulatory T Cells (Transplant Journal)
This study reports on engineered SC-islets that express CCL22 to recruit regulatory T cells at the graft site, reducing immune attack and enhancing survival in preclinical models. (Lippincott Journals)
Why it’s high impact:
• Immune modulation is crucial for durable human islet implantation; regulating microenvironment via chemokines intersects with physical microenvironment strategies.
4) Dong L et al., 2025 — Stem Cell-Derived Islets — Progress and Challenges (The Innovation Medicine)
This comprehensive review contextualizes the therapeutic journey of stem cell-derived islets, including clinical progress such as NX-880 trials, underlying differentiation challenges, and obstacles in immune protection and long-term engraftment. (The Innovation)
Why it’s high impact:
• Integrates developmental, production, and clinical aspects of SC-islet therapies — excellent background to position Moraes’ microenvironment work within the field.
5) Lee J et al., 2025 — Stem Cell-Derived and Gene-Edited Islet Therapies (Diabetes & Metabolism Journal)
This editorial review summarizes the new era of SC-islet and gene-edited islet therapies, highlighting innovations such as hypoimmune platforms engineered to evade immune rejection — central to long-term implantation success. (PubMed)
Why it’s high impact:
• Reflects the growing trend toward genetic and immunologic engineering to make implanted islets more durable — a key translational goal for clinical application.
Why these papers matter together
These 5 papers span the continuum from bench to bedside:
📌 NEJM clinical trial — first robust human efficacy data for stem-cell derived islets (zimislecel) (2025). (PubMed)
📌 Manufacturing scale-up work — critical for translating differentiation innovations into clinical-grade supply chains. (Nature)
📌 Immune modulation strategies — moving beyond production to graft survival & integration. (Lippincott Journals)
📌 Field overviews — integrating production, differentiation, and implantation challenges. (The Innovation)
Taken together, they sketch the state of play in 2025–2026: improving differentiation quality, manufacturing at scale, and overcoming immunologic hurdles — all highly relevant to microenvironmental control efforts like those of Moraes, which impact both upstream production and downstream transplantation outcomes.
